Klotho: The Longevity Protein
A circulating protein named after the Greek goddess of life-thread spinning. Overexpression extends mouse lifespan ~30%; deficiency accelerates aging. In 2026, multiple human trials are testing whether boosting Klotho is therapeutically viable.
Extension (Overexpr.)
Volunteers (2026)
Persistence Target
Klotho is a circulating anti-aging protein whose overexpression extends mouse lifespan ~30% and which declines with age in humans. Multiple 2026 human trials (IV mRNA and gene therapy) are testing whether raising it is viable. Whether boosting Klotho extends human lifespan or healthspan remains unknown.
How It Works
Klotho is an obligate co-receptor for fibroblast growth factor 23 (FGF23) in renal phosphate handling. The shed extracellular domain (sKlotho) circulates and acts independently as an anti-aging signal.
sKlotho dampens excessive Wnt signaling (linked to senescence) and inhibits IGF-1 receptor signaling — both pathways implicated in aging and age-related disease.
Single dose of αKL-F (a Klotho fragment) enhances cognition and synaptic plasticity in aged primates. Higher endogenous Klotho correlates with better human cognition in observational studies.
Klotho-deficient mice show vascular calcification, sarcopenia, hypogonadism, and emphysema. Higher Klotho associates with reduced cardiovascular events in aging cohorts.
What the Data Shows
Key Takeaways
- Discovered by Makoto Kuro-o; mouse Klotho overexpression extends lifespan ~30%
- Acts as obligate FGF23 co-receptor; shed soluble form (sKlotho) acts as a circulating anti-aging signal
- Klotho declines progressively with human age and correlates with healthspan biomarkers
- Klothea Bio launched phase 1b of AKL003 (IV mRNA Klotho therapy) in February 2026
- Minicircle is developing a Klotho plasmid gene therapy (subcutaneous) targeting ~1-year expression
- Klotho Neurosciences (NASDAQ: KLTO) developing diagnostic "Klotho Clock"
- Whether raising Klotho in healthy humans extends lifespan or healthspan
- Optimal therapeutic format — infused protein vs mRNA vs gene therapy
- Long-term safety of chronic Klotho elevation (interactions with FGF23 and phosphate balance)
- Whether oral/exercise-induced Klotho elevation produces clinical benefit
- Translation from rodent models to humans (a recurring longevity-research caveat)
Frequently Asked Questions
What is Klotho?
Klotho is a circulating anti-aging protein discovered by Makoto Kuro-o in 1997. The α-Klotho gene encodes a single-pass transmembrane protein expressed primarily in kidney, parathyroid, and brain. Its extracellular domain is shed as soluble Klotho (sKlotho) that circulates and acts on distant tissues. Mouse overexpression extends lifespan ~30%; deficiency causes accelerated aging.
Can humans take Klotho supplements?
No oral Klotho supplement has been validated. Klotho is a 130 kDa protein and would not survive digestion. Therapeutic strategies in active human development use IV mRNA (Klothea Bio AKL003), subcutaneous plasmid gene therapy (Minicircle), and small-molecule Klotho enhancers — all investigational. Exercise and certain calorie-restriction protocols modestly raise endogenous Klotho.
What human trials are running in 2026?
Klothea Bio launched a phase 1b randomized double-blind placebo-controlled trial of AKL003, an IV alpha-Klotho mRNA therapeutic, in February 2026. The study enrolls 21 healthy adults aged 25–75 at the GARM Clinic in Honduras, with two IV doses ~4 weeks apart. Endpoints include safety, tolerability, circulating sKlotho levels, and exploratory healthspan biomarkers.
Is the Minicircle Klotho gene therapy real?
Yes. Minicircle uses a non-integrating plasmid delivered via subcutaneous fat injection that drives Klotho expression for approximately one year per treatment. A proof-of-concept trial is underway with broader rollout in 2026. It is investigational, paid out-of-pocket, and outside conventional FDA regulatory pathways (offered in jurisdictions with permissive medical-tourism frameworks).
Does exercise raise Klotho?
Yes — modestly. Acute aerobic exercise raises serum sKlotho transiently; chronic exercise training elevates baseline sKlotho in older adults. Magnitudes are small relative to therapeutic strategies but represent the most accessible lever today.
🛒 Recommended Products
Support supplements and gear relevant to this protocol.
Affiliate links — support HighPeptides at no extra cost.
47-page guide: protocols, dosing, sourcing — everything in one place.
Get the guide — $19 (normally $29) → New to peptides? Start with the $19 Buyer’s Playbook → All ebooks & guides →Educational purposes only. Not medical advice.
No FDA-approved Klotho therapeutic exists as of April 2026; trials are investigational.
Get the Free 2026 Peptide Protocol Stack
Twelve compounds across four pillars — metabolic, tissue repair, longevity, cognitive. Citations included, formatted to print. Sent straight to your inbox.